The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

Diabetes Care

Volumn 36, Issue 4, 2013, Pages 858-864

  Meneghini, Luigi ^a   Atkin, Stephen L ^b   Gough, Stephen C L ^c   Raz, Itamar ^d   Blonde, Lawrence ^e   Shestakova, Marina ^f   Bain, Stephen ^g   Johansen, Thue ^h   Begtrup, Kamilla ^h   Birkeland, Kåre I ⁱ  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HULL   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e OCHSNER MEDICAL CENTER   (United States)

^f N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^g SINGLETON HOSPITAL   (United Kingdom)

^h NOVO NORDISK A S   (Denmark)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FLEXPEN; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN GLARGINE; INSULIN GLULISINE; METFORMIN; SOLOSTAR; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN TREATMENT; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED;

EID: 84875444482     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1668     Document Type: Article

References (28)

1. International Diabetes Federation. Diabetes Atlas. 5th ed. Brussels, Belgium, International Diabetes Federation, 2011
2. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-1596
4. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559
5. Lantus. European Public Assessment Report, Annex I: summary of product characteristics [Internet]. Available from http://www .ema.europa.eu/docs/en-GB/ document- library/EPAR-Product-Information/ human/000284/WC500036082.pdf. Accessed 17 October 2011
6. Levemir. European Public Assessment Report, Annex I: summary of product characteristics [Internet]. Available from http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/ human/000528/WC500036662. pdf. Accessed 17 October 2011
7. Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulindependent diabetesmellitus. The DARTS/ MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 1997;350: 1505-1510
8. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care 2005;28:78-83
9. Randløv J, Poulsen JU. How much do forgotten insulin injections matter to hemoglobin A1c in people with diabetes? A simulation study. J Diabetes Sci Tech 2008;2:229-235
10. Rajagopalan R, Joyce A, Smith D, Ollendorf D, Murray FT. Medication compliance in type 2 diabetes: retrospective data analysis (Abstract). Value Health 2003;6:328
11. Donnelly LA, Morris AD, Evans JM; DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007;100:345-350
12. Brod M, Rana A, Barnett AH. Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced doses. Curr Med Res Opin 2012;28:1933-1946
13. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-2545
14. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010;33:240-245
15. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy Study. Diabet Med 2012;29:682-689
16. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14: 859-864
17. Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine (Abstract). Diabetologia 2011;54:S425
18. Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec (Abstract). Diabetologia 2011;54:S426
19. Heise T, Nosek L, Bøttcher SG, HastrupH, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14:944-950
20. World Medical Association Inc. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc 2009;107:403-405
21. ICH Harmonised Tripartite Guideline: guideline for good clinical practice. J Postgrad Med 2001;47:199-203
22. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002;25: 876-882
23. Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J ImmunolMethods 2004;289:1-16
24. Food and Drug Administration. Food and Drug Administration, Code of Federal Regulations, Guidance for Industry, Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. Draft Guidance [Internet]. Available from http://www.fda.gov/downloads/Drugs/ ../Guidances/ucm071624.pdf. Accessed 17 October 2011
25. Garber AJ, King AB, Del Prato S, et al.; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultralongacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1498-1507
26. Zinman B, Philis-Tsimikas A, Cariou B, et al.; on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35:2464-2471
27. Bergenstal R, Bhargava A, Jain R, et al. 200 U/mL insulin degludec improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve people with type 2 diabetes (Abstract). American Association of Clinical Endocrinologists 21st Annual Scientific Meeting and Clinical Congress 2012;A266
28. Heller S, Buse J, Fisher M, et al.; BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target noninferiority trial. Lancet 2012;379:1489-149